The biotech company Xantium will spin off from its current corporate structure, ending its affiliation with a firm controlled by billionaire investor Paul Tudor Jones II. The separation is expected to take place in the coming year, marking a significant shift in the company’s operational and financial independence. This move could reshape Xantium’s strategic direction and market positioning as it prepares to operate as a standalone entity. Investors and industry observers will be watching closely to see how the transition unfolds.
Xantium to separate from company controlled by billionaire Paul Tudor Jones II next year
